Iovance Biotherapeutics Inc (IOVA)

[badgerkid]

The point of the previous article is once again to show Merck's efforts to maintain market presence for Keytruda, their big money maker. Trials for Keytruda and various combos have been halted quite a bit over the past 12 months, but Merck's combo with Iovance's Amtagvi still stands up and needs to be recognized. I don't know if anything is going on behind closed doors at this time, but it's a card that may need to be played and could push Merck to finally make a play to acquire Iovance and add TIL therapy to its stable.